SCHEMBL34461077

SCHEMBL34461077

CC[C@H](C)[C@H](N)C(=O)N[C@@H](CC(=O)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)O)C(C)C

nearest known ligand 0.58

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ CXCR4 P61073 8/20 0.58
▸ NPY1R P25929 1/20 0.57
▸ NPY2R P49146 1/20 0.57
▸ NPY4R P50391 1/20 0.57
▸ NPY5R Q15761 1/20 0.57
▸ C5AR1 P21730 1/20 0.55
▸ IL23R Q5VWK5 1/20 0.55
▸ MC4R P32245 2/20 0.54
▸ MC5R P33032 2/20 0.54
▸ MC3R P41968 2/20 0.54
▸ MC1R Q01726 2/20 0.54
▸ KEAP1 Q14145 1/20 0.52
▸ DPP3 Q9NY33 2/20 0.51
▸ KISS1R Q969F8 3/20 0.51
▸ EPHA2 P29317 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31001651 0.98 CXCR4 (0.59) CXCR4NPY1RNPY2RNPY4RNPY5R
SCHEMBL34461097 0.96 CXCR4 (0.59) CXCR4NPY1RNPY2RNPY4RNPY5R
SCHEMBL31001650 0.94 CXCR4 (0.61) CXCR4NPY1RNPY2RNPY4RNPY5R
SCHEMBL34461103 0.93 CXCR4 (0.66) CXCR4C5AR1IL23RMC4RMC5R
SCHEMBL34461114 0.92 DPP3 (0.55) CXCR4NPY1RNPY2RNPY4RNPY5R
SCHEMBL34461095 0.90 CXCR4 (0.68) CXCR4C5AR1IL23RKISS1R
SCHEMBL34461110 0.90 DPP3 (0.53) CXCR4C5AR1IL23RDPP3KISS1R
SCHEMBL34461090 0.89 DPP3 (0.59) CXCR4C5AR1IL23RMC4RMC5R
SCHEMBL29675119 0.88 CXCR4 (0.59) CXCR4IL23RKISS1R
SCHEMBL29674929 0.88 CXCR4 (0.59) CXCR4IL23RKISS1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260098072-A1 METHODS OF STIMULATING APPETITE AND/OR INCREASING BODY WEIGHT USING NON-NATURALLY OCCURRING MELANOCORTIN RECEPTOR ANTAGONIST ANALOGS ENDEVICA BIO INC (US) 2026-04-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260098072-A1 METHODS OF STIMULATING APPETITE AND/OR INCREASING BODY WEIGHT USING NON-NATURALLY OCCURRING MELANOCORTIN RECEPTOR ANTAGONIST ANALOGS MC1R, MC4R, MC5R CXCR4 2538/4885NPY1R 10/4885NPY2R 17/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback